Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Filings indexed 1,039 across all filing types
Latest filing 2012-10-03 Director's Dealing
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
STOCK OPTION GRANT 09/28/2012
Director's Dealing
2012-10-03 English
STOCK OPTION DATED 09/28/2012
Director's Dealing
2012-10-03 English
STOCK OPTION GRANT 09/28/2012
Director's Dealing
2012-10-03 English
SABBY ARWR 13G 08.16.12
Major Shareholding Notification
2012-08-16 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Arrowhead Research Corporation. It details the terms of the offering, including the number of units, pricing, placement agent fees, and other offering specifics. The document is a formal offering document used to raise capital through the issuance of common stock and warrants. This type of document is classified as a Capital/Financing Update (CAP) because it provides detailed information about a new financing transaction and securities issuance. It is not an annual or quarterly report, earnings release, or any other type of regulatory filing. The length and content confirm it is a full prospectus supplement, not merely an announcement or a brief notice.
2012-08-14 English
FORM 10-Q
Interim / Quarterly Report Q3 2012
2012-08-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.